Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Envelope glycoprotein 41 (gp41) is a transmembrane subunit of the HIV-1 envelope glycoprotein complex, which plays a central role in viral entry into host cells. It mediates fusion between viral and cellular membranes—a crucial step for HIV entry. After initial attachment via gp120 to CD4 and coreceptor (CCR5 or CXCR4), conformational changes expose and activate gp41, which inserts its fusion peptide into the target cell membrane. Refolding brings viral and cellular membranes together, facilitating their merger and allowing delivery of viral genetic material into the host cell cytoplasm. Peptides mimicking its heptad repeats can inhibit infection by blocking six-helical bundle formation.
Inhibition of six-helix bundle formation, preventing membrane fusion
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Envelope Glycoprotein 41 (gp41).